Associazione Nazionale Medici Cardiologi Ospedalieri

www.anmco.it

CONGRESS ABSTRACT

CONGRESS ABSTRACT

Categorie
The adding value of non-invasive assessment of stroke volume during cardiopulmonary exercise testing in hypertrophic cardiomyopathy: beyond O2-pulse
Anno:
2025
Background: in hypertrophic cardiomyopathy (HCM), cardiopulmonary exercise testing (CPET) is the gold standard for evaluating impaired exercise tolerance. The O2-pulse is calculated as oxygen uptake/heart rate, and it is used as a surrogate for stroke volume (SV). Abnormal O2-pulse kinetics suggests inadequate SV increase. Research question: since reduction of…
Leggi di più
HYPERTROPHIC CARDIOMYOPATHY IN FOCUS: CLINICAL CHARACTERISTICS, GENETIC INFLUENCES, AND PROGNOSTIC IMPLICATIONS
Anno:
2025
Introduction Hypertrophic Cardiomyopathy (HCM) ranges from asymptomatic cases to severe symptoms and life-threatening complications. This study aims to evaluate clinical features, genetic factors, echocardiographic findings, and progression toward advanced stages or SCD of a large cohort of HCM patients. Methods We retrospectively analyzed 413 HCM patients (50% obstructive; 63.4% male;…
Leggi di più
LONG-TERM CLINICAL OUTCOME OF NEONATAL ONSET HYPERTROPHIC CARDIOMYOPATHY ASSOCIATED TO NOONAN SYNDROME AND MITOCHONDRIAL DISEASES
Anno:
2025
BACKGROUND: Hypertrophic Cardiomyopathy (HCM) presenting during the neonatal period has different etiologies, risk factors, and clinical course comparing to HCM with onset during childhood, adolescence or adult age. Noonan and mitochondrial disease have the worst prognosis among all neonatal HCM. PURPOSE: We aim to describe the clinical course and…
Leggi di più
Changes in CMR-derived global longitudinal strain, progression of fibrosis and outcome in hypertrophic cardiomyopathy
Anno:
2025
Background: Hypertrophic cardiomyopathy (HCM) is a major health concern, with cardiac magnetic resonance (CMR) playing a crucial role in risk assessment. The utility of sequential CMR, particularly strain analysis, for tracking HCM progression remains to be established. Methods: We evaluated HCM patients undergoing two CMR scans over 10 years….
Leggi di più
Compassionate use program with mavacamten in patients with hypertrophic obstructive cardiomyopathy: first insights from a single-centre real world experience
Anno:
2025
Introduction: Mavacamten, a first-in-class cardiac myosin ATPase inhibitor used as second-line therapy for hypertrophic obstructive cardiomyopathy (HOCM),  became available in Italy in early 2024 under a compassionate use program.  Aim: To describe early experience of compassionate use of Mavacamten in a single centre HOCM population.  Methods: All patients had…
Leggi di più
Mavacamten, a real game changer in a case of hypertrophic cardiomyopathy with both midventricular and left ventricular outflow tract obstruction
Anno:
2025
A 27-year-old male was diagnosed at the age of 15 with sarcomeric hypertrophic obstructive cardiomyopathy (HOCM) (MYH-7 gene, variant c1816 G>A). No comorbidities. Patient underwent periodic follow-ups showing a predominant mid-ventricular obstruction with evolution in apical aneurysm. He was on beta-blockers. Due to massive septal hypertrophy (30 mm), extensive…
Leggi di più
The embolic dilemma: a rare case of chest pain dued to splenic infarction in a patient with coexisting apical HCM and PFO
Anno:
2025
Introduction Acute left-sided abdominal pain radiated to the left shoulder due to splenic infarction can be confused with cardiogenic thoracic pain. Splenic infarction is frequently linked to infiltrative hematologic disorders, but it can be also related to cardioembolic events. We present the case of a patient admitted to cardiology ward…
Leggi di più
The use of Levosimendan in Heart failure on Hypertrophic Cardiomyopathy
Anno:
2025
  A 65-year-old female patient with a diagnosis of hypertrophic cardiomyopathy, identified following the sudden death of her 10-year-old daughter. The cardiomyopathy initially presented in an obstructive form, with a maximum gradient of 90 mmHg at the left ventricular outflow tract. Coronary angiography showed no significant coronary abnormalities. Since…
Leggi di più
BEYOND THE RHYTHM – GENOMIC AND CLINICAL PROFILING OF INHERITED CARDIAC DISORDERS IN SOUTHERN ITALY
Anno:
2025
Inherited cardiac disorders encompass genetically diverse myocardial and electrical disturbances with substantial prognostic implications. This study investigated the genomic architecture and clinical manifestations of heritable cardiac conditions in a Southern Italian cohort of 363 families and 480 affected individuals. The phenotypic distribution showed predominance of structural myocardial disorders (69.95%)…
Leggi di più
Steroid-Induced Transient Obstructive Hypertrophic Cardiomyopathy in a six months old boy
Anno:
2025
  Background Steroid-induced hypertrophic cardiomyopathy is a rare complication in children undergoing prolonged corticosteroid therapy. Although typically reported in preterm neonates, this case in a six-month-old infant without pre-existing cardiac conditions broadens current understanding of this condition, highlighting the importance of thorough diagnostic and therapeutic approaches.    Case Description…
Leggi di più

A.N.M.C.O. – Via La Marmora 36, 50121 Firenze (Italy) – Partita I.V.A. 05469530488 – Codice Fiscale 01301130488 – Privacy
www.anmco.it | segreteria@anmco.it

Cookie Policy Privacy Policy

Seguici su

Facebook Twitter Youtube Linkedin Instagram Telegram